Dr. Horn on the Role of Mobocertinib in NSCLC

Leora Horn, MD, MSc, FRCPC, associate professor of cancer research, Vanderbilt Ingram Cancer Center, associate professor of medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, discusses the role of mobocertinib (TAK-788) in patients with non​–small cell lung cancer (NSCLC).

Mobocertinib is an EGFR TKI that is developed for the treatment of patients with EGFR exon 20–mutant and HER2-mutant NSCLC, says Horn.

Notably, minimal data are available with regard to patients with exon 20 insertions because it is a rare mutation that, historically, has not been responsive to first- or second-generation EGFR TKIs, Horn explains.

However, data compiled from Flat​iron Health proved beneficial in terms of comparing the responses of patients with exon 20 mutation​s who received traditional therapies with those ​who received mobocertinib on the phase 1/2 study (NCT02716116), Horn concludes.